Pathology and Forensic Medicine papers
Pofolia’s corpus holds 76 papers from Pathology and Forensic Medicine (2004–2026), each with a short summary. Below, the 20 most-cited, then the most recently added.
At a glance
- Most cited: Comprehensive molecular characterization of human colon and rectal cancer (2012, 8,699 citations).
- The 20 papers listed have 77,815 citations between them.
- 17 of the 19 with a known journal quartile appeared in a Q1 journal.
- 15 have a free full text (open access).
- Most frequent journals: New England Journal of Medicine, Journal of Clinical Oncology, Neurology.
- Published between 2012 and 2022.
Most cited
Ranked by citation count. Because citations accumulate over time, this list naturally leans towards work published a few years ago; for where the field is now, see “recently added”. How to read the signals
Comprehensive molecular characterization of human colon and rectal cancer
Nature · 2012 · Q1 · SJR 19.00 · FWCI 322.85 · 8,699 citations · Open access
A genome-wide analysis of 276 colorectal cancer samples reveals that 16% are hypermutated, with distinct causes, and identifies 24 significantly mutated genes, including new targets like ERBB2 and IGF2 amplifications.
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Blood · 2016 · Q1 · SJR 5.00 · FWCI 559.12 · 7,845 citations · Open access
The 2016 revision of the World Health Organization classification for lymphoid neoplasms updates diagnostic criteria, incorporates new provisional entities, and details the genetic and molecular landscape to guide more targeted therapies.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science · 2017 · Q1 · SJR 10.00 · FWCI 417.61 · 6,692 citations
Solid tumors with mismatch repair deficiency show a high response rate to PD-1 blockade therapy, with 53% objective radiographic responses and 21% complete responses across 12 tumor types.
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Journal of Clinical Oncology · 2014 · Q1 · SJR 4.00 · FWCI 145.01 · 5,589 citations · Open access
The Lugano Classification updates lymphoma staging and response assessment, formally incorporating FDG-PET-CT for staging FDG-avid lymphomas and modifying descriptive terminology.
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
Scientific Reports · 2021 · Q1 · FWCI 642.43 · 5,053 citations · Open access
Plasma levels of Heat shock protein 90 (Hsp90) are elevated in systemic sclerosis (SSc) patients compared to healthy controls and correlate with disease severity.
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Neurology · 2015 · Q1 · SJR 2.00 · FWCI 202.02 · 4,578 citations · Open access
New diagnostic criteria for neuromyelitis optica spectrum disorders (NMOSD) have been established, unifying the term and stratifying diagnoses based on the presence of aquaporin-4 IgG antibodies (AQP4-IgG).
New Multiple Sclerosis Phenotypic Classification
European Neurology · 2014 · Q2 · FWCI 257.45 · 4,261 citations
Multiple sclerosis (MS) phenotypes are updated to include clinically isolated syndrome and categorize all forms as active or non-active based on relapses and new MRI lesions.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Leukemia · 2022 · Q1 · SJR 3.00 · FWCI 438.40 · 3,799 citations · Open access
The upcoming 5th edition of the WHO Classification of Haematolymphoid Tumours introduces a hierarchical system for lymphoid neoplasms, alongside revised nomenclature, diagnostic criteria, and the inclusion of new entities and germline predisposition syndromes.
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
New England Journal of Medicine · 2014 · Q1 · SJR 18.00 · FWCI 243.91 · 3,562 citations · Open access
Nivolumab, a PD-1 blocking antibody, demonstrated substantial therapeutic activity in heavily pre-treated patients with relapsed or refractory Hodgkin's lymphoma, achieving an objective response rate of 87%.
2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Arthritis & Rheumatism · 2013 · FWCI 111.99 · 3,422 citations · Open access
New classification criteria for Systemic Sclerosis (SSc) have been developed by the ACR/EULAR, significantly improving sensitivity and specificity compared to the 1980 criteria.
Defining the clinical course of multiple sclerosis
Neurology · 2014 · Q1 · SJR 2.00 · FWCI 112.57 · 3,150 citations · Open access
International MS experts have refined clinical disease phenotypes by incorporating disease activity (relapse rate and imaging) and progression, addressing limitations of 1996 descriptors that lacked objective correlates.
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology · 2019 · Q1 · SJR 4.00 · FWCI 181.54 · 2,990 citations
In a Phase II trial of previously treated patients with advanced noncolorectal cancers deficient in DNA mismatch repair (dMMR/MSI-H), pembrolizumab achieved an objective response rate of 34.3%. This indicates significant clinical benefit for this specific patient population.
Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition
Multiple Sclerosis Journal · 2020 · Q1 · SJR 1.00 · FWCI 132.33 · 2,562 citations · Open access
The global prevalence of multiple sclerosis (MS) has increased since 2013, with an estimated 2.8 million people now living with the condition worldwide.
Multiple Sclerosis
New England Journal of Medicine · 2018 · Q1 · SJR 18.00 · FWCI 136.25 · 2,463 citations
Multiple sclerosis (MS) is a chronic, incurable autoimmune disease affecting over 2 million people globally.
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
Chemotherapy · 2017 · Q3 · FWCI 109.96 · 2,333 citations · Open access
Single-agent pixantrone induced remission in a patient with diffuse large B-cell lymphoma refractory to multiple prior chemotherapy regimens, successfully bridging them to autologous stem cell transplantation.
Myocardial ischemia-reperfusion injury: a neglected therapeutic target
Journal of Clinical Investigation · 2013 · Q1 · SJR 4.00 · FWCI 65.97 · 2,333 citations · Open access
Myocardial reperfusion, while crucial for treating heart attacks, paradoxically causes further heart muscle death (reperfusion injury) for which no effective therapy currently exists.
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2018 · Q1 · SJR 18.00 · FWCI 128.24 · 2,282 citations · Open access
Researchers have identified five distinct genetic subtypes of Diffuse Large B-Cell Lymphoma (DLBCL) based on shared genomic abnormalities, which correlate with different clinical outcomes and potential therapeutic vulnerabilities.
Multiple sclerosis – a review
European Journal of Neurology · 2018 · Q1 · SJR 1.00 · FWCI 59.88 · 2,126 citations · Open access
Multiple sclerosis (MS) is a growing global health concern, with increasing incidence and socioeconomic impact, yet its underlying causes and the reasons for its rise remain unclear.
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
BMJ · 2017 · Q1 · SJR 1.00 · FWCI 47.13 · 2,071 citations · Open access
Vitamin D supplementation significantly reduces the risk of acute respiratory tract infections (ARTIs) by 12% overall, with greater benefits observed in individuals with lower baseline vitamin D levels and those taking daily or weekly doses rather than bolus doses.
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Science · 2022 · Q1 · SJR 10.00 · FWCI 245.96 · 2,005 citations
Infection with the Epstein-Barr virus (EBV) is linked to a 32-fold increased risk of developing multiple sclerosis (MS), with neurodegeneration markers appearing only after EBV infection.
Recently added
Hunting for microsatellite instability in long-read data with Owl
PLoS Computational Biology · 2026 · Q1 · SJR 1.00 · FWCI 12.03 · 2 citations · Open access
Owl, a new bioinformatic tool, quantifies microsatellite instability (MSI) from long-read genomic data, identifying MSI in 6 cancer cell lines and one astrocytoma tumor with 10-27% unstable markers.
Lumbar disc herniation: Epidemiology, clinical and radiologic diagnosis WFNS spine committee recommendations
World Neurosurgery X · 2024 · Q1 · FWCI 25.10 · 87 citations
New WFNS Spine Committee guidelines recommend MRI as the gold standard for confirming lumbar disc herniation (LDH) and outline key clinical tests like manual muscle testing and Lasegue sign for diagnosis.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms
Leukemia · 2022 · Q1 · SJR 3.00 · FWCI 438.40 · 3,799 citations · Open access
The upcoming 5th edition of the WHO Classification of Haematolymphoid Tumours introduces a hierarchical system for lymphoid neoplasms, alongside revised nomenclature, diagnostic criteria, and the inclusion of new entities and germline predisposition syndromes.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
New England Journal of Medicine · 2022 · Q1 · SJR 18.00 · FWCI 189.28 · 1,569 citations
A neoadjuvant PD-1 blockade with dostarlimab resulted in a clinical complete response in all 10 patients with mismatch repair-deficient, locally advanced rectal cancer, eliminating the need for standard chemoradiotherapy and surgery.
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood · 2022 · Q1 · SJR 5.00 · FWCI 176.37 · 1,524 citations · Open access
A new International Consensus Classification (ICC) for mature lymphoid, histiocytic, and dendritic cell tumors has been proposed, incorporating recent genomic findings and refining diagnostic criteria.
The Lasegue test: Defining its specificity and sensitivity based on geometry
Clinical Anatomy · 2022 · Q1 · FWCI 0.41 · 3 citations
The Lasegue test's diagnostic accuracy for lumbar disc herniation is geometrically predictable, with sensitivity and specificity highest for lateral herniations at L4-5 (n=865).
Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis
Science · 2022 · Q1 · SJR 10.00 · FWCI 245.96 · 2,005 citations
Infection with the Epstein-Barr virus (EBV) is linked to a 32-fold increased risk of developing multiple sclerosis (MS), with neurodegeneration markers appearing only after EBV infection.
Diffuse Large B-Cell Lymphoma
New England Journal of Medicine · 2021 · Q1 · SJR 18.00 · FWCI 97.55 · 1,151 citations
Diffuse Large B-Cell Lymphoma (DLBCL) is an aggressive cancer representing 30% of lymphomas, with current standard chemotherapy curing approximately 65% of patients initially and an additional 20-25% with salvage therapy.
Journals in this field
The journals that publish most of this field’s papers. Quartile (Q1–Q4), SJR and h-index are from SCImago Journal Rank; “in this field” is how many of the journal’s pooled papers belong here. What is a Q1 journal? · What is the h-index?
| Journal | Quartile | SJR | h-index | In this field | Summaries |
|---|---|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 1275 | 13 | 376 |
| Journal of Clinical Oncology | Q1 | 4.00 | 666 | 4 | 38 |
| Blood | Q1 | 5.00 | 556 | 3 | 21 |
| Science | Q1 | 10.00 | 1433 | 2 | 268 |
| JAMA | Q1 | 5.00 | 818 | 2 | 114 |
| Neurology | Q1 | 2.00 | 435 | 2 | 12 |
| Nutrients | Q1 | 1.00 | 279 | 2 | 25 |
| European Neurology | Q2 | — | 96 | 2 | 4 |
Every journal in Pathology and Forensic Medicine (Q1–Q4) →
Add this field to your daily feed
Pick your interests and new work in your area arrives every day, summarised. Full summaries live in the app.
Open the app